CN108524595A - Chinese medicine composition is preparing the application in treating cerebral apoplexy drug - Google Patents
Chinese medicine composition is preparing the application in treating cerebral apoplexy drug Download PDFInfo
- Publication number
- CN108524595A CN108524595A CN201810642529.1A CN201810642529A CN108524595A CN 108524595 A CN108524595 A CN 108524595A CN 201810642529 A CN201810642529 A CN 201810642529A CN 108524595 A CN108524595 A CN 108524595A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- drug
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Chinese medicine compositions to prepare the application in treating cerebral apoplexy drug, specifically discloses a kind of Chinese medicine composition, and the Chinese medicine composition is the extract of Rhizoma Chuanxiong and pueraria lobata；Preferably, Rhizoma Chuanxiong, pueraria lobata are by weight 1:1 proportioning.Application of the Chinese medicine composition in the drug for preparing treatment cerebral apoplexy, it is preferable that the cerebral apoplexy is cerebral arterial thrombosis.
Description
Technical field
The invention belongs to pharmacology fields, and in particular to Chinese medicine composition is preparing the application in treating cerebral apoplexy drug.
Background technology
Cerebral arterial thrombosis (Cerebral ischemic stroke) is also known as Ischemic Cerebral Infarction, has high morbidity
The characteristics of rate, high disability rate and high mortality is the disease [1] for seriously endangering human life's safety.According to U.S. AHA
(American Heart Association) newest announcement data show that there are about 795,000 new hairs or recurrences every year for the whole America
Palsy case occurs an example apoplexy patient for average every 40 seconds, has a patient to die of palsy within every 4 minutes, the death rate is more than
60%.In all palsy cases, Ischemic Stroke accounts for about 87% [2].Studies have shown that cerebral arterial thrombosis is mainly
Caused by the blood vessel of brain specific region and its restricted reduction of the blood flow of branch vessel.It is acute when cerebral ischemia occurs
Anoxic causes energetic supersession to lack, and causes cerebral artery marginal belt ischemic lesions, and then lead to brain tissue subalimentation, generates inclined
The neurological dysfunctions such as paralysis, aphasia, hemianopsia symptom [3] threatens the primary of public health to ask currently, cerebral arterial thrombosis has become
Topic, causes also to bring white elephant to family and society while life threat to patient.
The cerebral arterial thrombosis interpretation of the cause, onset and process of an illness is complicated, and clinic is treated mainly for some part in pathologic process, including molten
Bolt, platelet aggregation-against, anti-freezing and neuroprotection etc. [4,5], currently, U.S. FDA approval is used to treat ischemic cerebral apoplexy
In intravenous thrombolysis drug only have rt-PA (rt-PA).The appearance of rt-PA is considered as ischemic
The breakthrough of cerebral apoplexy drug therapy is injected intravenously the rt-PA of 0.9mg/kg in China's cardiovascular and cerebrovascular diseases guideline of prevention and treatment
The standard regimens of findings in acute ischemic cerebral stroke are proposed as, but rt-PA thrombolysis time windows are only 3-5h, and is injected intravenously
Administering mode also bring such as respiratoring palpitating suddenly stopping adverse reaction [6] to patient, although moreover, the thrombolytic drugs such as rt-PA
Use can effectively improve the state of an illness in thrombolysis time window, but along with the unobstructed again of occluded blood vessel, when blood flow Reperfu- sion
The brain tissue of ischemic will appear the pathologic damages such as oedema, inflammatory reaction exacerbation, neuronal metabolic obstacle and Apoptosis, i.e.,
Ischemical reperfusion injury.Therefore, in clinical thromboembolism treatment, these disadvantages make answering using rt-PA as the thrombolytic drug of representative
With being further limited.Therefore, new therapy target is found, the drug for developing safe and effective treatment cerebral arterial thrombosis is urgently
Problem to be solved.
Chinese medicine has the characteristics that multicomponent, multiple target point, multipath pai n nursing, and many Chinese medicines are in treatment cardiovascular and cerebrovascular diseases side
Face applicating history is long, for example, chuanxiong, property is acrid in flavour and warm in nature, Return liver, courage, pericardium channel.With blood-activating and qi-promoting, wind-expelling pain-stopping it
Effect is usually used in chest impediment and cardialgia, chest side of body shouting pain, tumbling and swelling, irregular menstruation, closed dysmenorrhea , Disorder lump in the abdomen is suffered from abdominal pain, headache, rheumatism numbness
Pain etc..Studies have shown that the active ingredient ligustrazine and ferulic acid of Rhizoma Chuanxiong can obviously improve cardiovascular function.Ligustrazine has anti-blood
Bolt improves microcirculation, protection blood-brain barrier and coronary artery, effectively prevents cerebral ischemia and improves the pharmacology such as ischemical reperfusion injury
It acts on [7-9].Ferulic acid can effectively remove free radical, have the effects that anti-oxidant, reducing blood lipid, effectively prevent coronary heart disease [10].
As it can be seen that Rhizoma Chuanxiong is by removing, free radical, influencing the approach such as nerve cell apoptosis, inhibition inflammatory reaction, effectively prevention and treatment lack
Courageous and upright cerebral apoplexy [11].Chinese medicament kudzu-vine root is sweet, pungent, cool, returns spleen, stomach, lung channel.It brings down a fever, promotes the production of body fluid to quench thirst with expelling pathogenic factors from muscles and skin, promoting eruption rises
The effect of positive antidiarrheal, clearing and activating the channels and collaterals, relieving alcoholism.It is usually used in fever caused by exogenous pathogens headache, stiff nape and back, dizziness and headache, hemiplegia, chest
Numbness is pained, and wine poison wound is medium.There is significant ingredient Puerarin in pueraria lobata expansion peripheral blood vessel, reduction blood viscosity, protection to lack
The pharmacological activity such as blood cardiac muscle and brain tissue.Therefore, pueraria lobata curative effect in terms for the treatment of cardiovascular and cerebrovascular diseases has obtained recognizing for clinic already
It can.As it can be seen that Rhizoma Chuanxiong is curative for effect in terms for the treatment of cardiovascular and cerebrovascular diseases with pueraria lobata.Moreover, Chinese medicine is administered orally, compare
Injection is safer, and patient adaptability is good, is suitble to long term administration, and therefore, the present invention is directed to develop a kind of safe and effective more targets
Point treats and prevents the Pharmaceutical composition of cerebral arterial thrombosis.The present invention according to the pharmacological activity features of the Chinese medicines such as Rhizoma Chuanxiong, pueraria lobata,
Using traditional Chinese medicine compatibility theory as foundation, in conjunction with pharmacodynamic study, discloses and a kind for the treatment of and preventing the medicinal of cerebral arterial thrombosis
Composition.The pharmaceutical composition can be effectively improved nervous function damage, improvement blood lipid level and blood caused by cerebral arterial thrombosis
Fluid rheology feature, to be effectively prevented and treated cerebral arterial thrombosis.
Bibliography:
[1] gold phoenix, Zhang Zhefeng thank to the progress .J Apoplexy and of red risk factors of ischemic stroke forever
Nervous Diseases.2017,34(8):764-765
[2].Benjamin EJ,Blaha MJ,Chiuve SE,et al.Heart disease and stroke
statistics-2017update:A report from the American Heart
Association.Circulation,2017,135(10):e146-e603
[3] solves red, Liu Xuezheng, the pathogenesis and Research Advance on Risk Factors of Liu Xinqiao progressive ischemic strokes
[J] combination of Chinese tradiational and Western medicine cardiovascular and cerebrovascular diseases magazine [J] .2016,14 (6):612-614
[4] Hu Ya, Yang Zhihong, Sun Xiao wave .JAK/STAT signal transduction pathways and Chinese medicine intervention are in cerebral arterial thrombosis
Progress [J] Chinese Pharmacological Bulletins, 2016, (07):889-894.
[5] Chen Dong, Zhao Guide examines Norcent cerebral arterial thrombosis study of incident mechanism new development [J] foreign medical sciences (god
Neurosurgery fascicle is learned through disease) .2001,28 (1):32-34.
[6] jades, Xu Chaoqing, the treatment acute cerebral infarction cause of Wang Yingrui Recombinant Human Tissue Typceplasminogen Activators are exhaled
Inhale 1 report [J] .2015 of cardiac arrest, 32 (9)：846-847
[7] Yang Xue plums ligustrazines Advance on Pharmacological Activities [J] China biochemical drug magazine, 2010,31 (03):
215-217.
[8] Jiang Yu are diligent, skilful ligustrazines Advance on Pharmacological Activities [J] the contemporary Chinese Chinese medicines of wangdan, 2016,18 (10):
1364-1370
[9] in Jiang Yue suedes, CHEN Ke ji ligustrazine cardio-cerebrovascular pharmacological actions and clinical application research progress [J]
State recycles magazine, 2013,28 (Z1):229
[10] Europe bodyguard benefit, Bao Huiyan, Advance on Pharmacological Activities [J] Chinese medicines of blue will east ferulic acid and its derivatives
Material, 2001,24 (03):220-221.
[11] the bent friends of are straight, and Gao Guodong, ligustrazine and its drug combination treat cerebral ischemia re-pouring injured progress
Chinese Clinical rehabilitation, 2004,8 (19):3862-3863
Invention content
The present invention relates to a kind of Pharmaceutical compositions for preventing and treating cerebral arterial thrombosis.The composition is to ischemic institute
The cerebral injury of cause has good protective effect, can effectively prevent and treat cerebral arterial thrombosis, have to cardiovascular and cerebrovascular diseases auxiliary
The therapeutic effect helped.The composition is mainly made of following raw material：Rhizoma Chuanxiong or Rhizoma Chuanxiong extract and pueraria lobata or kudzu root extract, two
The weight proportion of person ranging from Rhizoma Chuanxiong or 1~50 part of Rhizoma Chuanxiong extract, pueraria lobata or 1~200 part of kudzu root extract.The pharmaceutical compositions
Object, which can combine to be made individually or with pharmaceutic adjuvant, is suitable for oral dosage form.
One aspect of the invention provides a kind of Chinese medicine composition, and the Chinese medicine composition is the extraction of Rhizoma Chuanxiong and pueraria lobata
Object；Preferably, Rhizoma Chuanxiong, pueraria lobata are by weight 1:1 proportioning.
Another aspect of the invention provides the preparation method of the Chinese medicine composition, the wherein extraction of Rhizoma Chuanxiong and pueraria lobata
Object is prepared by the following method to obtain：Rhizoma Chuanxiong, pueraria lobata are weighed, 10 times of volume of water are added or alcohol reflux extraction, filtering take filtrate
It is spare, 3~20 times of volume of water or/and alcohol reflux extraction, filtering are added again, merges filtrate twice, clear cream is made in concentration,
0.8mg/g containing Puerarin or more wherein in clear cream.
One aspect of the invention provides application of the Chinese medicine composition above-mentioned in the drug for preparing treatment cerebral apoplexy, excellent
Selection of land, the cerebral apoplexy are cerebral arterial thrombosis.
One aspect of the invention provides Chinese medicine composition above-mentioned and is preparing the blood fat caused by reducing cerebral arterial thrombosis
The application in drug in exception.
It is that total cholesterol and triglyceride levels increase that one aspect of the invention, which provides aforementioned dyslipidemia,.
One aspect of the invention provides Chinese medicine composition above-mentioned and is preparing reduction ischemic cerebral apoplexy blood samples of patients viscosity
Drug in application.
One aspect of the invention provides Chinese medicine composition above-mentioned and is preparing reduction ischemic cerebral apoplexy patient's fibrin
Application in the drug of original content.
It is poly- in preparation reduction ischemic cerebral apoplexy Platelet that one aspect of the invention provides Chinese medicine composition above-mentioned
Application in the drug of collection rate.
One aspect of the invention provides Chinese medicine composition above-mentioned and is preparing while reducing ischemic cerebral apoplexy blood samples of patients
Application in the drug of viscosity, fibrinogen concentration and platelet aggregation rate.
Method for preparing extractive：Weigh prepared slices of Chinese crude drugs Rhizoma Chuanxiong, appropriate pueraria lobata, be added 3~30 times of volume of water or (and) ethyl alcohol
Twice, filtering merges filtrate twice to refluxing extraction, and clear cream is made in concentration.A certain proportion of cane sugar powder, dextrin is added in qinghuo reagent
And ethyl alcohol is suitable, is made and is suitable for oral dosage form.
The purposes of drug：The present invention relates to a kind of Pharmaceutical compositions for preventing and treating cerebral arterial thrombosis.The medicine
It can obviously restore the nervous function damage caused by cerebral arterial thrombosis with composition, improve the blood caused by cerebral arterial thrombosis
Fat is abnormal, and can effectively reduce blood viscosity, fibrinogen and platelet aggregation rate, and the composition is to the brain caused by ischemic
Damage has good protective effect, and cerebral arterial thrombosis is effectively prevented and treated from multiple links.
The effect and drug of the purposes of drug realize the principle of its function：A kind of prevention and treatment ischemic of the present invention
Property cerebral apoplexy Pharmaceutical composition in containing there is expansion peripheral blood vessel, reduce blood viscosity, antithrombotic, improve microcirculation and other effects
Active constituent, can significantly restore the nervous function damage caused by cerebral arterial thrombosis, improve caused by cerebral arterial thrombosis
Dyslipidemia, and blood viscosity, fibrinogen content and platelet aggregation rate can be effectively reduced, to change from many aspects
The complication that kind cerebral arterial thrombosis induces, it is believed that, which can effectively treat and prevent cerebral arterial thrombosis.
3~30g of taking dose.
Description of the drawings
Fig. 1 is behaviouristics Neuroscore.
Fig. 2 is the full brain coloration result figures of TTC.
Fig. 3 is triglyceride concentration each group result figure.
Fig. 4 is total cholesterol concentration each group result figure.
Fig. 5 is each group result figure of blood viscosity shear rate 200m Pa S.
Fig. 6 is each group result figure of blood viscosity shear rate 5m Pa S.
Fig. 7 is each group result figure of fibrinogen concentration.
Fig. 8 is each group result figure of platelet aggregation rate.
Specific implementation mode
The preparation method of 1 Chinese medicine composition of embodiment
Rhizoma Chuanxiong, appropriate pueraria lobata are weighed, by weight 1:1 mixing, be added 10 times of volume of water or (and) alcohol reflux extract 1h,
Filtering, takes filtrate spare, be added again 3-20 times of volume of water or (and) alcohol reflux extraction, filtering merges filtrate twice, dense
Clear cream (containing Puerarin 0.83mg/g) is made in contracting.A certain proportion of cane sugar powder, dextrin and appropriate amount of ethanol is added in qinghuo reagent, is made
It is suitable for oral dosage form.
2 Rhizoma Chuanxiong of embodiment, pueraria lobata Pharmaceutical composition can obviously restore the nervous function damage caused by cerebral arterial thrombosis
Experimental method：
Experiment packet：Healthy SD rat 50, male, weight 240-280g are randomly divided into Normal group, ischemic
Cerebral apoplexy model group, physiological saline group, positive drug group, drug-treated group.Normal group：Rat is without any processing, only
Physiological saline is given according to weight.Cerebral arterial thrombosis group：Prepare arteria cerebri media embolism model (Middle on the right side of rat
Cerebral Artery Occlusion, MCAO) after, Reperfu- sion 2 hours is put to death.Physiological saline group：It prepares big on the right side of rat
In brain after arterial embolism model (MiddleCerebral Artery Occlusion, MCAO), Reperfu- sion 2 hours, later continuously
Physiological saline, positive drug group were given once daily according to weight in 14 days：It prepares on the right side of rat after arteria cerebri media embolism model, then fills
Note 2 hours gives Buddhist nun Moses plain film (190mg/kg) in continuous 14 days later according to weight；Drug-treated group：It prepares on the right side of rat
After arteria cerebri media embolism model, Reperfu- sion 2 hours gives pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition in continuous 14 days later according to weight
(based on Puerarin 50mg/kg).
It is prepared by model：Arteria cerebri media embolism (Middle CerebralArtery on the right side of rat are prepared using line brush
Occlusion, MCAO) model, scores to its nervous function with reference to Longa point systems, has investigated its Behavioral feature.
The result is shown in Figure 1, the results showed that, after modeling, when rat autokinetic movement, topples over to the left, and neurological functional deficit scale is 3 points,
Think to have resulted in severe focal lesion.Meanwhile full brain is dyed using TTC decoration methods, as a result see Fig. 2 and table a.
The full brains of table a TTC dye infarct rate
The result shows that after modeling, rat cerebral infarction percentage reaches 38.81 ± 4.91, the above Neuroscore and TTC
Coloration result shows successfully to establish infarction area after cerebral middle artery occlusion in rats model, can be with the disease of accurate simulation cerebral arterial thrombosis
Diseased state.Fig. 1 Neuroscores result and Fig. 2 and the full brain TTC coloration results prompts of table a, when cerebral arterial thrombosis occurs
Afterwards, it is always 3 points that rat nerve functional impairment degree scored within 14 day observation period, and at 14 days, and right side brain still can water breakthrough
It swells, collapse, show that cerebral arterial thrombosis can cause nervous function and brain tissue impairment, and this nervous function damage not can self
Restore, but after pueraria lobata, the treatment of Rhizoma Chuanxiong Pharmaceutical composition, Neuroscore significantly reduces, and brain edema is alleviated obviously, such as
Fig. 1, Fig. 2 and watch a are as it can be seen that pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition can fast quick-recovery nervous function damages caused by cerebral arterial thrombosis
Cerebral injury is injured, improves cerebral arterial thrombosis symptom in terms of subordinate act.
3 Rhizoma Chuanxiong of embodiment, pueraria lobata Pharmaceutical composition can improve the dyslipidemia caused by cerebral arterial thrombosis
Oral Administration in Rats has been investigated using Nimodipine as positive control drug using arteria cerebri media embolism model on the right side of rat
Blood lipid level after pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition.Serum triglyceride (TG), total cholesterol (T-CHO) content are all made of phase
Kit is answered to detect, concrete operations by specification executes, and kit information is shown in Table b.As a result see Fig. 3, Fig. 4, table c, table d.
The information table of table b kits
Table c triglycerides (TG) concentration
Table d total cholesterols (TCHO) concentration
The result shows that after infarction area after cerebral middle artery occlusion in rats, total cholesterol and triglyceride levels significantly increase, and prompt ischemic
Property cerebral apoplexy can induce dyslipidemia, rat modeling and after giving physiological saline 14 days, total cholesterol and triglyceride levels with
Cerebral arterial thrombosis group is close, does not show to be decreased obviously, and give pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition rat total cholesterol
It is significantly reduced with triglyceride levels, and horizontal closer to Normal group, total cholesterol is compared with Normal group without aobvious
Difference is write, shows that the hyperlipidemia state induced by cerebral arterial thrombosis can be effectively relieved in pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition.
4 Rhizoma Chuanxiong of embodiment, pueraria lobata Pharmaceutical composition can effectively reduce blood viscosity, fibrinogen and platelet aggregation
Rate
Oral Administration in Rats has been investigated using Nimodipine as positive control drug using arteria cerebri media embolism model on the right side of rat
Blood viscosity, fibrinogen and platelet aggregation rate after pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition.Blood viscosity, fibrin
Former and platelet aggregation rate is measured using SA-9000 fully automatic blood rheology analysis instrument (Succeeder, China).It measures
Whole blood viscosity under high-rate of shear (200mPas) and low shear rate (5mPas).Result of study shows ischemic
Cerebral apoplexy can increase blood viscosity, fibrinogen content and platelet aggregation rate, to increase the risk of thrombosis.But
Give pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition rat blood viscosity, fibrinogen content and platelet aggregation rate significantly under
Drop, shows that pueraria lobata, Rhizoma Chuanxiong Pharmaceutical composition can effectively reduce blood viscosity, fibrinogen and platelet aggregation rate.As a result
See Fig. 5 to Fig. 8 and table e to table h.
Table e whole blood viscosity (blood viscosity, 200m Pa S)
Table f whole blood viscosity (blood viscosity, 5m Pa S)
Table g fibrinogens (Fibrinogen) concentration
Table h platelet aggregation rates (Platelet aggregation rate)
Claims (9)
1. a kind of Chinese medicine composition, the Chinese medicine composition is the extract of Rhizoma Chuanxiong and pueraria lobata；Preferably, Rhizoma Chuanxiong, pueraria lobata are pressed
Weight ratio 1:1 proportioning.
2. the extract of the preparation method of Chinese medicine composition according to claim 1, wherein Rhizoma Chuanxiong and pueraria lobata passes through following
Method is prepared：Rhizoma Chuanxiong, pueraria lobata are weighed, 10 times of volume of water are added or alcohol reflux extraction, filtering take filtrate spare, again
3~20 times of volume of water or/and alcohol reflux extraction, filtering is added, merges filtrate twice, clear cream is made, wherein in clear cream in concentration
0.8mg/g containing Puerarin or more.
3. application of the Chinese medicine composition according to claim 1 in the drug for preparing treatment cerebral apoplexy, it is preferable that described
Cerebral apoplexy be cerebral arterial thrombosis.
4. a kind of application of Chinese medicine composition in the drug in preparing the dyslipidemia caused by reducing cerebral arterial thrombosis.
5. application according to claim 4 increases wherein the dyslipidemia is total cholesterol and triglyceride concentration.
6. a kind of application of Chinese medicine composition in preparing the drug for reducing ischemic cerebral apoplexy blood samples of patients viscosity.
7. a kind of application of Chinese medicine composition in preparing the drug for reducing ischemic cerebral apoplexy patient's fibrinogen concentration.
8. a kind of application of Chinese medicine composition in preparing the drug for reducing ischemic cerebral apoplexy Platelet aggregation rate.
9. a kind of Chinese medicine composition is preparing while reducing ischemic cerebral apoplexy blood samples of patients viscosity, fibrinogen concentration and blood
Application in the drug of platelet aggregation rate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810642529.1A CN108524595A (en) | 2018-06-21 | 2018-06-21 | Chinese medicine composition is preparing the application in treating cerebral apoplexy drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810642529.1A CN108524595A (en) | 2018-06-21 | 2018-06-21 | Chinese medicine composition is preparing the application in treating cerebral apoplexy drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108524595A true CN108524595A (en) | 2018-09-14 |
Family
ID=63471392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810642529.1A Pending CN108524595A (en) | 2018-06-21 | 2018-06-21 | Chinese medicine composition is preparing the application in treating cerebral apoplexy drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524595A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857385A (en) * | 2005-05-08 | 2006-11-08 | 谢秀琼 | Medicine composition for treating cervical spondylosis and its preparing method |
| CN103768114A (en) * | 2012-10-23 | 2014-05-07 | 成都康弘药业集团股份有限公司 | Application of pharmaceutical composition in preparation of medicines used for treating or preventing cerebral apoplexy |
-
2018
- 2018-06-21 CN CN201810642529.1A patent/CN108524595A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857385A (en) * | 2005-05-08 | 2006-11-08 | 谢秀琼 | Medicine composition for treating cervical spondylosis and its preparing method |
| CN103768114A (en) * | 2012-10-23 | 2014-05-07 | 成都康弘药业集团股份有限公司 | Application of pharmaceutical composition in preparation of medicines used for treating or preventing cerebral apoplexy |
Non-Patent Citations (3)
| Title |
|---|
| 倪根珊: "《药物临床应用撷萃》", 31 August 1994, 八一出版社 * |
| 蔡传钢等: "川芎嗪注射液联合葛根素治疗缺血性脑卒中的临床研究", 《中国民族民间医药》 * |
| 陈可冀: "《川芎嗪的化学、药理与临床研究》", 31 March 1998, 人民卫生出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8883228B2 (en) | Composition for heart disease, its active ingredients, method to prepare same and uses thereof | |
| WO2004012651A2 (en) | Composition for heart disease, method to prepare same and uses thereof | |
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
| CN108175795A (en) | A kind of plaster | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN103721094A (en) | Health-care tea for reducing blood pressure | |
| CN110898201B (en) | A topical Chinese medicinal composition for removing food stagnation in children, and its preparation method | |
| CN115414407B (en) | Zhuang medicine compound medicine for treating ischemic cerebral apoplexy and preparation method thereof | |
| CN102940668B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN108524595A (en) | Chinese medicine composition is preparing the application in treating cerebral apoplexy drug | |
| CN105943595B (en) | Medicine for treating hand-foot syndrome caused by chemotherapy and hand-foot skin reaction caused by targeted therapy and preparation method thereof | |
| CN101632756B (en) | Traditional Chinese medicine for treating malignant tumours and preparation method thereof | |
| CN101450189B (en) | Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN109481656B (en) | Medicine for treating senile dementia | |
| CN101342208B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia and preparation method thereof | |
| CN104324135A (en) | Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition | |
| CN115813972B (en) | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN102626479B (en) | External-use Chinese herbal medicine composition for chronic rheumatism treatment | |
| CN102526544B (en) | Oral powder Chinese medicine formula for treating lumbar disc herniation and osteoproliferation | |
| CN101884735B (en) | Medicament for treating dyslipidemia and preparation method thereof | |
| CN105012855A (en) | Medicine composition for treating stroke, as well as preparation method and application thereof | |
| CN105125886A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications of diabetes | |
| CN105106855A (en) | Traditional Chinese medicine preparation for treating apoplexy sequela |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180914 |
|
| RJ01 | Rejection of invention patent application after publication |